Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator? - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Clinical Research in Cardiology Année : 2022

Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?

Résumé

Sudden cardiac death (SCD) is the most frequent cause of cardiovascular death in industrialized nations. Patients with cardiomyopathy are at increased risk for SCD and may benefit from an implantable cardioverter-defibrillator (ICD). The risk of SCD is highest in the first months after myocardial infarction or first diagnosis of severe non-ischemic cardiomyopathy. On the other hand, left ventricular function may improve in a subset of patients to such an extent that an ICD might no longer be needed. To offer protection from a transient risk of SCD, the wearable cardioverter-defibrillator (WCD) is available. Results of the first randomized clinical trial investigating the role of the WCD after myocardial infarction were recently published. This review is intended to provide insight into data from the VEST trial, and to put these into perspective with studies and clinical experience. As a non-invasive, temporary therapy, the WCD may offer advantages over early ICD implantation. However, recent data demonstrate that patient compliance and education play a crucial role in this new concept of preventing SCD.
Fichier principal
Vignette du fichier
Israel2022_Article_SuddenCardiacDeathWhileWaiting.pdf (853.54 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03629505 , version 1 (04-04-2022)

Licence

Paternité

Identifiants

Citer

Carsten Israel, Ingo Staudacher, Christophe Leclercq, Giovanni Luca Botto, Daniel Scherr, et al.. Sudden cardiac death while waiting: do we need the wearable cardioverter-defibrillator?. Clinical Research in Cardiology, 2022, 111 (11), pp.1189-1197. ⟨10.1007/s00392-022-02003-4⟩. ⟨hal-03629505⟩
70 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More